{"id":"NCT00236184","sponsor":"Eisai Inc.","briefTitle":"E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers","officialTitle":"E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2006-03","completion":"2008-06","firstPosted":"2005-10-12","resultsPosted":"2009-10-01","lastUpdate":"2010-04-06"},"enrollment":629,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Heartburn"],"interventions":[{"type":"DRUG","name":"rabeprazole sodium","otherNames":["Aciphex"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Rabeprazole sodium 10 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the safety and efficacy of rabeprazole sodium 10 mg in treating frequent heartburn.","primaryOutcome":{"measure":"Complete Heartburn Relief During the First Full 24-Hour Period in the ITT Population.","timeFrame":"first 24 hours","effectByArm":[{"arm":"Placebo","deltaMin":114,"sd":null},{"arm":"Rabeprazole 10 mg","deltaMin":163,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"19 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":310},"commonTop":["Nasopharyngitis"]}}